9 results
Pharmacologic treatment algorithms by Global Initiative for Chronic Obstructive Lung Disease grade. Highlighted boxes and arrows
Pharmacologic treatment ... muscarinic antagonist; LABA ... #Management #Pulmonary ... COPD #GOLD2017 #LAMA ... #LABA #ICS #Guidelines
Medical Treatment Algorithm for Chronic Obstructive Pulmonary Disease
Initial medical treatment of chronic obstructive pulmonary disease (COPD)
corticosteroid; LABA ... long-acting β2-agonist; LAMA ... #Algorithm #Management ... #Pulmonary #LABA ... #LAMA #SABA #SAMA
The 2019 Global Initiative for Asthma (GINA) treatment strategy figure for adults and adolescents, annotated to
receptor antagonists; LABA ... volume in 1 s; IL ... #GINA #Asthma #Management ... #Stepwise #Pulmonary ... #Algorithm #Guidelines
Prostanoid prescribing and management in Pulmonary Arterial Hypertension (PAH)
Oral Prostanoids:
 - Selexipag
 - Treprostinil
Inhaled Prostanoids
 -
prescribing and management ... in Pulmonary Arterial ... Hypertension (PAH ... #Management #Algorithm ... #treatment #pharmacology
Low / Intermediate Risk Pulmonary Arterial Hypertension (PAH) Management Algorithm

Dr. John Ryan @JJRyanMD

#Pulmonary #Arterial #Hypertension #PAH
Hypertension (PAH ... ) Management Algorithm ... #Hypertension #PAH ... #Management #Algorithm ... #treatment #pharmacology
LABA/ICS Combination Inhalers
Long-Acting Beta2 Agonists (LABA) + Inhaled Corticosteroid (ICS) - Commonly used in Asthma 
Advair
LABA/ICS Combination ... Beta2 Agonists (LABA ... Here are the LABA ... These combo LABA ... algorithm).
It is important to recognize Acute Decompensated Heart Failure (ADHF) as more than just simply a
with presence of pulmonary ... is vital while lab ... #differential #algorithm ... #management #cardiology ... icu #clinical #pharmacology
Amiodarone Induced Lung Toxicity Summary

Who?
• 5% of patients
• Dose ≥ 400 mg per day

How?  Possible
starting amiodarone treatment ... pneumonia, ARDS, DAH ... Exclusion of other ILDs ... Labs: • Nonspecific ... #diagnosis #management
Sjogren's Syndrome Overview

Epidemiology:
• F > M: 9:1
• 5-6th Decades (can be any age)

Autoimmune exocrinopathy multisystemic disease
Ocular examination Labs ... amyloidosis, PAH ... Adenocarcinoma Treatment ... lubricants • Pharmacologic ... Rheumatology #Diagnosis #Management